arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2018-24-1-29-40arthyper-756Research ArticleОРИГИНАЛЬНАЯ СТАТЬЯORIGINAL ARTICLEГИПЕРТРОФИЧЕСКАЯ КАРДИОМИОПАТИЯ В СТАРШЕЙ ВОЗРАСТНОЙ ГРУППЕ: ВЛИЯНИЕ ФАКТОРОВ КАРДИОМЕТАБОЛИЧЕСКОГО РИСКА И ПОЛИМОРФИЗМА ГЕНА MADDHYPERTROPHIC CARDIOMYOPATHY IN THE OLDER AGE GROUP: THE EFFECT OF CARDIOMETABOLIC RISK FACTORS AND RS2290149 AND RS10838692 OF THE MADD GENEПоляковаА. А.PoliakovaA. A.

Полякова Анжелика Александровна — старший научный сотрудник научно-исследовательского отдела инфильтративных заболеваний сердца Института молекулярной биологии и генетики;  младший научный сотрудник лаборатории кардиомиопатий Института сердечно-сосудистых заболеваний. 

Санкт-Петербург.

St. Petersburg.

lica.polyakova@mail.ruГудковаА. Я.GudkovaA. Yu.

Гудкова Александра Яковлевна — доктор медицинских наук, профессор, ведущий научный сотрудник Института молекулярной биологии и генетики;  заведующая лабораторией кардиомиопатий Института сердечно-сосудистых заболеваний. 

Санкт-Петербург.

St. Petersburg.

КрутиковА. Н.KrutikovA. N.

Крутиков Александр Николаевич — ведущий научный сотрудник научно-исследовательского отдела инфильтративных заболеваний сердца Института молекулярной биологии и генетики.

Санкт-Петербург.

St. Petersburg.

СемернинЕ. Н.SemerninE. N.

Семернин Евгений Николаевич — кандидат медицинских наук, руководитель научно-исследовательского отдела инфильтративных заболеваний сердца Института молекулярной биологии и генетики. 

Санкт-Петербург.

St. Petersburg.

КозленокА. В.KozlenokA. V.

Козленок Андрей Валерьевич — кандидат медицинских наук, заведующий научно-исследовательским отделом физиологии кровообращения.

Санкт-Петербург.

St. Petersburg.

ПыкоС. А.PykoS. A.

Пыко Светлана Анатольевна — кандидат технических наук, старший научный сотрудник научно-исследовательского отдела инфильтративных заболеваний сердца Института молекулярной биологии и генетики. 

Санкт-Петербург.

St. Petersburg.

КостареваА. А.KostarevaA. A.

Костарева Анна Александровна — кандидат медицинских наук, директор Института молекулярной биологии и генетики. 

Санкт-Петербург.

St. Petersburg.

ШляхтоЕ. В.ShlyakhtoE. V.

Шляхто Евгений Владимирович — доктор медицинских наук, профессор, академик РАН, заслуженный деятель науки РФ, генеральный директор;   заведующий кафедрой терапии факультетской с курсом эндокринологии, кардиологии и функциональной диагностики имени Г. Ф. Ланга с клиникой; президент Российского кардиологического общества, главный кардиолог Санкт-Петербурга и Северо-Западного федерального округа.

Санкт-Петербург.

St. Petersburg.

Федеральное государственное бюджетное учреждение   «Национальный медицинский исследовательский центр  имени В. А. Алмазова» Министерства здравоохранения   Российской Федерации; Федеральное государственное бюджетное образовательное  учреждение высшего образования   «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова»   Министерства здравоохранения Российской Федерации.РоссияAlmazov National Medical Research Centre; First Pavlov State Medical University of St. Petersburg.Russian FederationФедеральное государственное бюджетное учреждение   «Национальный медицинский исследовательский центр  имени В. А. Алмазова» Министерства здравоохранения   Российской Федерации.РоссияAlmazov National Medical Research Centre.Russian Federation2018120320182412940Copyright © Полякова А.А., Гудкова А.Я., Крутиков А.Н., Семернин Е.Н., Козленок А.В., Пыко С.А., Костарева А.А., Шляхто Е.В., 20182018Полякова А.А., Гудкова А.Я., Крутиков А.Н., Семернин Е.Н., Козленок А.В., Пыко С.А., Костарева А.А., Шляхто Е.В.Poliakova A.A., Gudkova A.Y., Krutikov A.N., Semernin E.N., Kozlenok A.V., Pyko S.A., Kostareva A.A., Shlyakhto E.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/756гипертрофия левого желудочка различного генезаидиопатическая гипертрофическая кардиомиопатиягипертрофия левого желудочкафакторы кардиометаболического рискаполиморфные варианты гена MADDкоморбидная патологияleft ventricular hypertrophy of various originidiopathic hypertrophic cardiomyopathyleft ventricular hypertrophycardiometabolic risk factorspolymorphic variants of MADD genecomorbiditiesReferencesElliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35 (39):2733–2779. doi:10.1093/eurheartj/ehu284Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35 (39):2733–2779. doi:10.1093/eurheartj/ehu284Ciro E, Nichols PF, Maron BJ. Heterogeneous morphologic expression of genetically transmitted hypertrophic cardiomyopathy. Two-dimensional echocardiographic analysis. Сirculation. 1983;67 (6):1227–33. doi:10.1161/01.CIR.67.6.1227Ciro E, Nichols PF, Maron BJ. Heterogeneous morphologic expression of genetically transmitted hypertrophic cardiomyopathy. Two-dimensional echocardiographic analysis. Сirculation. 1983;67 (6):1227–33. doi:10.1161/01.CIR.67.6.1227Olivotto I, Girolami F, Nistri S, Rossi A, Rega L, Garbini F et al. The many faces of hypertrophic cardiomyopathy: from developmental biology to clinical practice. J Cardiovasc Transl Res. 2009;2:349–367. doi:10.1007/s12265–009–9137–2Olivotto I, Girolami F, Nistri S, Rossi A, Rega L, Garbini F et al. The many faces of hypertrophic cardiomyopathy: from developmental biology to clinical practice. J Cardiovasc Transl Res. 2009;2:349–367. doi:10.1007/s12265–009–9137–2Wang P, Zou Y, Fu C, Zhou X, Hui R. MYBPC3 polymorphism is a modifier for expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. Biochem Biophys Res Commun. 2005;329(2):796–9.Wang P, Zou Y, Fu C, Zhou X, Hui R. MYBPC3 polymorphism is a modifier for expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. Biochem Biophys Res Commun. 2005;329(2):796–9.Marian AJ. Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol. 2002;17(3):242–52. doi:10.1097/01.HCO. 0000013803.40803.6AMarian AJ. Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol. 2002;17(3):242–52. doi:10.1097/01.HCO. 0000013803.40803.6ABrugada R, Kelsey W, Lechin M, Zhao G, Yu QT, Zoghbi W et al. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. J Investig Med. 1997;45(9):542–51.Brugada R, Kelsey W, Lechin M, Zhao G, Yu QT, Zoghbi W et al. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. J Investig Med. 1997;45(9):542–51.Wu CK, Huang YT, Lee JK, Chiang LT, Chiang FT, Huang SW et al. Cardiac myosin binding protein C and MAPkinase activating death domain-containing gene polymorphisms and diastolic heart failure. Plos One. 2012;4(7): e35242. doi:10.1371/journal.pone.0035242Wu CK, Huang YT, Lee JK, Chiang LT, Chiang FT, Huang SW et al. Cardiac myosin binding protein C and MAPkinase activating death domain-containing gene polymorphisms and diastolic heart failure. Plos One. 2012;4(7): e35242. doi:10.1371/journal.pone.0035242Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10(1):45–65.Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10(1):45–65.Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001;11(9):372–377.Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001;11(9):372–377.Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214(2):149–160.Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214(2):149–160.Yokoyama T, Nakano M, Bednerczyk JL, Mclntyre BW, Entman M, Mann DL et al. Tumor necrosis factor-a provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997;95(5):1247–52.Yokoyama T, Nakano M, Bednerczyk JL, Mclntyre BW, Entman M, Mann DL et al. Tumor necrosis factor-a provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997;95(5):1247–52.Olivotto I, Maron BJ, Tomberli B, Appelbaum E, Salton C, Haas TS et al. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;62 (5):449–57. doi:10.1016/j.jacc.2013.03.062Olivotto I, Maron BJ, Tomberli B, Appelbaum E, Salton C, Haas TS et al. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;62 (5):449–57. doi:10.1016/j.jacc.2013.03.062Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008;88 (2):389–419. doi:10.1152/physrev. 00017.2007Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008;88 (2):389–419. doi:10.1152/physrev. 00017.2007Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med. 1985;312(5):277–83. doi:10.1056/NEJM198501313120504Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med. 1985;312(5):277–83. doi:10.1056/NEJM198501313120504Karam R, Lever HM, Healy BP. Hypertensive hypertrophic cardiomyopathy or hypertrophic cardiomyopathy with hypertension? A study of 78 Patients. J Am Coll Cardiol. 1989;13(3):580–4. doi:10.1016/0735–1097(89)90596–2Karam R, Lever HM, Healy BP. Hypertensive hypertrophic cardiomyopathy or hypertrophic cardiomyopathy with hypertension? A study of 78 Patients. J Am Coll Cardiol. 1989;13(3):580–4. doi:10.1016/0735–1097(89)90596–2Shimizu M, Sugihara N, Shimizu K, Yoshio H, Ino H, Nakajima K et al. Asymmetrical septal hypertrophy in patients with hypertension: a type of hypertensive left ventricular hypertrophy or hypertrophic cardiomyopathy combined with hypertension? Clin Cardiol. 1993;16(1):41–6. doi:10.1002/clc.4960160110Shimizu M, Sugihara N, Shimizu K, Yoshio H, Ino H, Nakajima K et al. Asymmetrical septal hypertrophy in patients with hypertension: a type of hypertensive left ventricular hypertrophy or hypertrophic cardiomyopathy combined with hypertension? Clin Cardiol. 1993;16(1):41–6. doi:10.1002/clc.4960160110Avelar E, Cloward TV, Walker JM, Farney RJ, Strong M, Pendleton RC et al. Left ventricular hypertrophy in severe obesity: interactions among blood pressure, nocturnal hypoxemia, and body mass. Hypertension. 2007;49(1):34–9. doi:10.1161/01.HYP. 0000251711.92482.14Avelar E, Cloward TV, Walker JM, Farney RJ, Strong M, Pendleton RC et al. Left ventricular hypertrophy in severe obesity: interactions among blood pressure, nocturnal hypoxemia, and body mass. Hypertension. 2007;49(1):34–9. doi:10.1161/01.HYP. 0000251711.92482.14Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. J Am Med Assoc. 1991;266(2):231–236. doi:10. 1001/jama.1991.03470020057032Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. J Am Med Assoc. 1991;266(2):231–236. doi:10. 1001/jama.1991.03470020057032Гудкова А. Я. Клинико-морфологические сопоставления и механизмы гипертрофии при обструктивной гипертрофической кардиомиопатии: дис. … д-ра мед. наук: кардиология — 14.00.06, патологическая анатомия — 14.00.15. СанктПетербургский государственный медицинский университет имени академика И. П. Павлова. 2006. 380 c. [Gudkova AYa. Clinical and morphological comparisons and mechanisms of hypertrophy in obstructive hypertrophic cardiomyopathy. Dissertatsiya doktora meditsinskih nauk: kardiologiya — 14.00.06, patologicheskaya anatomiya — 14.00.15. Saint-Petersburg Pavlov Medical University. 2006. 380 p. In Russian].Гудкова А. Я. Клинико-морфологические сопоставления и механизмы гипертрофии при обструктивной гипертрофической кардиомиопатии: дис. … д-ра мед. наук: кардиология — 14.00.06, патологическая анатомия — 14.00.15. СанктПетербургский государственный медицинский университет имени академика И. П. Павлова. 2006. 380 c. [Gudkova AYa. Clinical and morphological comparisons and mechanisms of hypertrophy in obstructive hypertrophic cardiomyopathy. Dissertatsiya doktora meditsinskih nauk: kardiologiya — 14.00.06, patologicheskaya anatomiya — 14.00.15. Saint-Petersburg Pavlov Medical University. 2006. 380 p. In Russian].Uwaifo GI, Fallon EM, Calis KA, Drinkard B, McDuffie JR, Yanovski JA. Improvement in hypertrophic cardiomyopathy after significant weight loss: case report. South Med J. 2003;96(6):626– 31. doi:10.1097/01.SMJ.0000053254.23595.14Uwaifo GI, Fallon EM, Calis KA, Drinkard B, McDuffie JR, Yanovski JA. Improvement in hypertrophic cardiomyopathy after significant weight loss: case report. South Med J. 2003;96(6):626– 31. doi:10.1097/01.SMJ.0000053254.23595.14Wong C, Marwick TH. Obesity cardiomyopathy: diagnosis and therapeutic implications. Nat Clin Pract Cardiovasc Med. 2007;4(9):480–90. doi:10.1038/ncpcardio0964Wong C, Marwick TH. Obesity cardiomyopathy: diagnosis and therapeutic implications. Nat Clin Pract Cardiovasc Med. 2007;4(9):480–90. doi:10.1038/ncpcardio0964Di Bello V, Santini F, Di Cori A, Pucci A, Palagi C, Delle Donne MG et al. Obesity cardiomyopathy: is it a reality? An ultrasonic tissue characterization study. J Am Soc Echocardiogr. 2006;19(8):1063–71. doi:10.1016/j.echo.2006.03.033Di Bello V, Santini F, Di Cori A, Pucci A, Palagi C, Delle Donne MG et al. Obesity cardiomyopathy: is it a reality? An ultrasonic tissue characterization study. J Am Soc Echocardiogr. 2006;19(8):1063–71. doi:10.1016/j.echo.2006.03.033Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol. 1992;70(9):921–4. doi:10.1016/0002– 9149 (92)90739-LKasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol. 1992;70(9):921–4. doi:10.1016/0002– 9149 (92)90739-LCanepa M, Sorensen LL, Pozios I, Dimaano VL, HongChang L, Pinheiro AC et al. Comparison of clinical presentation, left ventricular morphology and hemodynamics, and exercise tolerance in obese versus non-obese patients with hypertrophic cardiomyopathy. Am J Cardiol. 2013;112(8):1182–1189. doi:10. 1016/j.amjcard.2013.05.070Canepa M, Sorensen LL, Pozios I, Dimaano VL, HongChang L, Pinheiro AC et al. Comparison of clinical presentation, left ventricular morphology and hemodynamics, and exercise tolerance in obese versus non-obese patients with hypertrophic cardiomyopathy. Am J Cardiol. 2013;112(8):1182–1189. doi:10. 1016/j.amjcard.2013.05.070Ommen SR, Lopez-Jimenez F. Obesity and hypertrophic cardiomyopathy: chickens, eggs, and causality: clinical skills remain the key to caring for patients. J Am Coll Cardiol. 2013;62 (5):458–9. doi:10.1016/j.jacc.2013.03.063Ommen SR, Lopez-Jimenez F. Obesity and hypertrophic cardiomyopathy: chickens, eggs, and causality: clinical skills remain the key to caring for patients. J Am Coll Cardiol. 2013;62 (5):458–9. doi:10.1016/j.jacc.2013.03.063Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol. 2011;58(23):2432–2446. doi:10.1016/j.jacc.2011.10.824Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol. 2011;58(23):2432–2446. doi:10.1016/j.jacc.2011.10.824Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Despres JP, Ndumele CE et al. The cardio metabolic health alliance: working toward a new care model for the metabolic syndrome. J Am Coll Cardiol. 2015;66(9):1050–1067. doi:10.1016/j.jacc.2015. 06.1328Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Despres JP, Ndumele CE et al. The cardio metabolic health alliance: working toward a new care model for the metabolic syndrome. J Am Coll Cardiol. 2015;66(9):1050–1067. doi:10.1016/j.jacc.2015. 06.1328Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52. doi:10.1161/CIRCULATIONAHA.105. 169404Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52. doi:10.1161/CIRCULATIONAHA.105. 169404Alberti KG, Zimmet P, Shaw J. The metabolic syndrome — a new worldwide definition. Lancet. 2005;366 (9491):1059–1062. doi:10.1016/S0140–6736 (05)67402–8Alberti KG, Zimmet P, Shaw J. The metabolic syndrome — a new worldwide definition. Lancet. 2005;366 (9491):1059–1062. doi:10.1016/S0140–6736 (05)67402–8Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120 (16):1640–1645. doi:10.1161/CIRCULATIONAHA.109.192644Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120 (16):1640–1645. doi:10.1161/CIRCULATIONAHA.109.192644Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16 (3):233–70. doi:10.1093/ehjci/jev014Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16 (3):233–70. doi:10.1093/ehjci/jev014Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277–314. doi:10.1093/ehjci/jew082Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277–314. doi:10.1093/ehjci/jew082Wong RC, Tan KB. Asymmetric left ventricular hypertrophy associated with morbid obesity mimicking familial hypertrophic cardiomyopathy. Singapore Med J. 2014;55(12): e201–4. doi:10. 11622/smedj.2014186Wong RC, Tan KB. Asymmetric left ventricular hypertrophy associated with morbid obesity mimicking familial hypertrophic cardiomyopathy. Singapore Med J. 2014;55(12): e201–4. doi:10. 11622/smedj.2014186Alpert MA, Fraley MA, Birchem JA, Senkottaiyan N. Management of obesity cardiomyopathy. Expert Rev Cardiovasc Ther. 2005;3(2):225–30. doi:10.1586/14779072. 3.2.225Alpert MA, Fraley MA, Birchem JA, Senkottaiyan N. Management of obesity cardiomyopathy. Expert Rev Cardiovasc Ther. 2005;3(2):225–30. doi:10.1586/14779072. 3.2.225Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Сirculation. 2000;102(16):1944–9. doi:10.1161/01.CIR.102.16.1944Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Сirculation. 2000;102(16):1944–9. doi:10.1161/01.CIR.102.16.1944

The authors declare that there are no conflicts of interest present.